مقاله انگلیسی یک نانو فرمولاسیون مبتنی بر سیکلودکسترین
ترجمه نشده

مقاله انگلیسی یک نانو فرمولاسیون مبتنی بر سیکلودکسترین

عنوان فارسی مقاله: یک نانو فرمولاسیون مبتنی بر سیکلودکسترین باعث تحویل مشترک جینسنوزید Rg3 و کوئرستین برای شیمی درمانی در سرطان روده بزرگ می شود
عنوان انگلیسی مقاله: A cyclodextrin-based nanoformulation achieves co-delivery of ginsenoside Rg3 and quercetin for chemo-immunotherapy in colorectal cancer
مجله/کنفرانس: Acta Pharmaceutica Sinica B
رشته های تحصیلی مرتبط: داروسازی، شیمی
گرایش های تحصیلی مرتبط: نانوفناوری دارویی، شیمی دارویی
کلمات کلیدی فارسی: سیستم تحویل دارو نانو ، شیمی درمانی ، ایمونوتراپی ، درمان ترکیبی ، مرگ سلول های ایمنی ، گونه های واکنش اکسیژن ، محیط ریز تومور ، سرطان روده بزرگ
کلمات کلیدی انگلیسی: Nano drug delivery system, Chemotherapy, Immunotherapy, Combination therapy, Immunogenic cell death, Reactive oxygen species, Tumor microenvironment, Colorectal cancer
نوع نگارش مقاله: مقاله پژوهشی (Research Article)
نمایه: Scopus - Master Journals List - JCR - DOAJ - PubMed Central
شناسه دیجیتال (DOI): https://doi.org/10.1016/j.apsb.2021.06.005
دانشگاه: Jilin University, China
ناشر: الزویر - Elsevier
نوع ارائه مقاله: ژورنال
نوع مقاله: ISI
سال انتشار مقاله: 2021
ایمپکت فاکتور: 10.621 در سال 2020
شاخص H_index: 51 در سال 2021
شاخص SJR: 1.912 در سال 2020
شناسه ISSN: 2211-3835
شاخص Quartile (چارک): Q1 در سال 2020
فرمت مقاله انگلیسی: PDF
تعداد صفحات مقاله انگلیسی: 45
وضعیت ترجمه: ترجمه نشده است
قیمت مقاله انگلیسی: رایگان
آیا این مقاله بیس است: بله
آیا این مقاله مدل مفهومی دارد: دارد
آیا این مقاله پرسشنامه دارد: ندارد
آیا این مقاله متغیر دارد: ندارد
کد محصول: E15485
رفرنس: دارای رفرنس در داخل متن و انتهای مقاله
نوع رفرنس دهی: vancouver
فهرست انگلیسی مطالب

Abstract


Graphical abstract


Keywords


Abbreviations


1. Introduction


2. Materials and methods


3. Results


4. Discussion


5. Conclusions


Author contributions


Declaration of Competing Interest


Acknowledgments


Appendix A. Supplementary data


References

نمونه متن انگلیسی مقاله

Abstract


The immune checkpoint blockade therapy has profoundly revolutionized the field of cancer immunotherapy. However, despite great promise for a variety of cancers, the efficacy of immune checkpoint inhibitors is still low in colorectal cancer (CRC). This is mainly due to the immunosuppressive feature of the tumor microenvironment (TME). Emerging evidence reveals that certain chemotherapeutic drugs induce immunogenic cell death (ICD), demonstrating great potential for remodeling the immunosuppressive TME. In this study, the potential of ginsenoside Rg3 (Rg3) as an ICD inducer against CRC cells was confirmed using in vitro and in vivo experimental approaches. The ICD efficacy of Rg3 could be significantly enhanced by quercetin (QTN) that elicited reactive oxygen species (ROS). To ameliorate in vivo delivery barriers associated with chemotherapeutic drugs, a folate (FA)-targeted polyethylene glycol (PEG)-modified amphiphilic cyclodextrin nanoparticle (NP) was developed for co-encapsulation of Rg3 and QTN. The resultant nanoformulation (CD-PEG-FA.Rg3.QTN) significantly prolonged blood circulation and enhanced tumor targeting in an orthotopic CRC mouse model, resulting in the conversion of immunosuppressive TME. Furthermore, the CD-PEG-FA.Rg3.QTN achieved significantly longer survival of animals in combination with Anti-PD-L1. The study provides a promising strategy for the treatment of CRC.


 


1. Introduction


As the third leading cause of cancer-related deaths worldwide (e.g., 881,000 deaths estimated in 2018)1, colorectal cancer (CRC, a cancer of the colon or rectum) is an obvious disease burden requiring effective, safe and widely-applicable treatments. Recent research in cancer immunology has led to the development of different immunotherapeutic strategies2, 3, 4. Among these, strategies that exert the blockade of immune checkpoint pathways [e.g., cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1)] have achieved favorable outcomes in a range of solid tumors5. However, it has been reported that only a minority of patients (up to 15% of the CRC population), who are identified with mismatch repair (MMR)-deficient CRC, respond positively to immune checkpoint blockade therapy6, while the response rate remains low in MMR-proficient CRC patients7. This failure is strongly attributed to the immunosuppressive feature of the tumor microenvironment (TME)8. Therefore, approaches designed to reprogram the TME may improve the therapeutic efficacy of immune checkpoint inhibitors9, potentially providing therapeutic benefit for the wide spectrum of CRC patients.


Immunogenic cell death (ICD) is characterized as immunogenic apoptosis that activates damage-associated molecular patterns (DAMPs) in dying or dead tumor cells in response to certain stimuli10. DAMPs as danger signals activate dendritic cells (DCs) for the presentation of tumor-associated antigens (TAAs), which subsequently induce T cell-mediated immunological responses against living tumor cells of the same kind10. The concept of ICD has revolutionized the traditional view of chemotherapeutic agents that are considered cytotoxic and poorly immunogenic. For example, chemotherapeutic drugs such as anthracyclines11, oxaliplatin12, bortezomib13 and cardiac glycosides14 have been identified as the putative ICD inducers. Recently, evaluation of chemotherapeutics as potential ICD inducers has gained increasing attention. In addition, ICD is often concomitant with the production of reactive oxygen species (ROS)10, and the efficacy of ICD may be enhanced by ROS-inducing strategies15, 16, 17. Therefore, it is hypothesized that a combination of ICD- and ROS-inducing strategies will mediate the remodeling of immunosuppressive TME and achieve synergistic immunotherapeutic efficacy with immune checkpoint blockade.

  • اشتراک گذاری در

دیدگاه خود را بنویسید:

تاکنون دیدگاهی برای این نوشته ارسال نشده است

مقاله انگلیسی یک نانو فرمولاسیون مبتنی بر سیکلودکسترین
نوشته های مرتبط
مقالات جدید
نماد اعتماد الکترونیکی
پیوندها